Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674 · View on ClinicalTrials.gov ↗
Study Summary
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG NX-1607
Study Locations (17)
Other
- Addenbrookes Cambridge University Hospital — Cambridge
- Beatson West of Scotland Cancer Centre — Glasgow
- Sarah Cannon Research Institute — London
- The Christie NHS Foundation Trust — Manchester
- Northern Centre for Cancer Care — Newcastle
- Churchill Hospital — Oxford
California
- City of Hope — Duarte
- University of Southern California — Los Angeles
- University of California, San Francisco — San Francisco
Colorado
- University of Colorado School of Medicine — Aurora
Illinois
- University of Chicago — Chicago
North Carolina
- University of North Carolina — Chapel Hill
Oklahoma
- University of Oklahoma — Oklahoma City
Texas
- MD Anderson Cancer Center — Houston
Virginia
- University of Virginia — Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05107674
The ClinicalTrials.gov registry entry for NCT05107674 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nurix Therapeutics, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions — of which Paclitaxel is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05107674 reports 17 study locations spanning 10 distinct geographic areas — top geographies include Other, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05107674 about?
NCT05107674 is a clinical study titled "A Study of NX-1607 in Adults With Advanced Malignancies". This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
What is the current status of trial NCT05107674?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 345 participants. The study started on 2021-09-29. Estimated completion is 2028-02-28.
What conditions does trial NCT05107674 study?
This clinical trial studies the following conditions: Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05107674?
The interventions under investigation include: Paclitaxel (DRUG), NX-1607 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05107674?
This trial is sponsored by Nurix Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05107674 being conducted?
This trial has 17 study locations across California, Colorado, Illinois, North Carolina, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.